Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer
Clinical trial NCT06259058 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06259058
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-04-01
- Primary completion
- 2026-04-01
- Enrollment
- 96
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.